sdbn.org

SAN DIEGO, CA March 18, 2010- Somaxon Pharmaceuticals, Inc. (Nasdaq: SOMX) today announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for Silenor (doxepin) for the treatment of insomnia characterized by difficulty with sleep maintenance.

Sleep maintenance difficulty, defined as waking frequently during the night and/or waking too early... More...

Xconomy.com -- Elcelyx Therapeutics of San Diego has raised $1.2 million of a planned $2.2 million equity offering, according to an SEC filing. The document says the companys president is Alain D. Baron, entrepreneur in residence at Morgenthaler Ventures in Menlo Park. Morgenthaler partner Ralph Chris Christofferson is an Elcelyx board member, according to the filing. More...

SAN DIEGO, March 18 /PRNewswire-FirstCall/ -- Orexigen(R) Therapeutics, Inc. , a biopharmaceutical company focused on the treatment of obesity, today announced that the Company will be speaking at Barclays Capital 2010 Global Healthcare Conference.

About Orexigen Therapeutics

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the... More...

SAN DIEGO, March 19 /PRNewswire/ -- Stemedica Cell Technologies, Inc. (Stemedica), a world leader in stem cell research and manufacturing, announced that it has filed an Investigative New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for a clinical trial. The trial will assess the safety, tolerability and efficacy of Stemedica's high potency proprietary allogeneic mesenchymal... More...

Elcelyx Therapeutics of San Diego has raised $1.2 million of a planned $2.2 million equity offering, according to an SEC filing. The document says the company’s president is Alain D. Baron,...

[[Click headline to continue reading.]] More...

After three tries, Somaxon Pharmaceuticals has won FDA approval for its insomnia drug. The San Diego-based biotech company said today it has gotten clearance to start selling doxepin (Silenor) in the...

[[Click headline to continue reading.]] More...

It must be nice to be the CEO of a life sciences company that sells itself. When Tina Nova stepped up to the microphone at the Roth Capital Partners Growth Stock Conference in Laguna Niguel, CA,...

[[Click headline to continue reading.]] More...

Regulatory news dominated the headlines in the past week. We have it summarized for you here. —Sequenom (NASDAQ: SQMN) said a lack of adequate controls, protocols and supervision were to blame...

[[Click headline to continue reading.]] More...

SAN DIEGO, March 17, 2010 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market (Nasdaq:MNOV) and the Hercules Market of the Osaka Securities Exchange (Code Number: 4875), today reported positive preliminary results from a Phase Ib clinical trial to evaluate the safety and efficacy of MN-221 in patients with stable, moderate to severe... More...

SAN DIEGO, March 17, 2010 (GLOBE NEWSWIRE) -- Harbor BioSciences, Inc. (Nasdaq:HRBR) today announced that NASDAQ has approved its application to transfer its stock listing to The Nasdaq Capital Market (the "Capital Market") from The Nasdaq Global Market, effective at the opening of business on March 18, 2010. The company's common stock will continue to be traded under the symbol "HRBR." The Nasdaq... More...